StockData

Arrowhead Pharmaceuticals vs Monopar Therapeutics

ARWR and MNPR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARWR and MNPR compare

Arrowhead Pharmaceuticals is the larger company, worth 13 times as much as Monopar Therapeutics ($6.2B against $483M).

Monopar Therapeutics scores higher on the StockData Score (7 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARWRMNPR
Size and price
Market cap$6.2B$483M
Share price$44.21$71.97
Change, 1 year7.5%−17.3%
Change, 5 years−38.6%197%
Beta (5Y)1.530.66
Employees71122
StockData Score
Total score57 (better)
Valuation score00
Growth score2 (better)0
Performance score2 (better)1
Health score16 (better)
Dividend score00
Valuation
P/S9.3×–
P/B13.4×3.7× (better)
FCF yield−1.2%–
Fair value$32.18–
Margin of safety−37.4%–
Growth
Revenue growth (TTM)16.8%–
Revenue growth, 5Y average56.6%–
Profitability
Operating margin−33.8%–
Net margin−47.8%–
FCF margin−11.2%–
Return on equity−64.8%−19.5% (better)
Financial health
Debt / equity–0.00
Interest coverage−2.4×–
Current ratio5.9033.56 (better)
Altman Z-score1.7569.88 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions84.6%92.7%
Held by insiders4.0%–
Insider net buying, 12 months−$36.9M−$5.6M (better)
Short interest, % of float8.5%–

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.